CLAIMS

1. A compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



(I)

wherein:

R^1 represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, $-S(O)_nC_{1-6}$alkyl, $-S(O)_nC_{1-6}$haloalkyl and pentafluorothio;

R^2 represents ~~hydrogen~~, halo, cyano, nitro, ~~C_{1-6} alkyl~~, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl, C_{2-6} haloalkynyl, $-S(O)_nC_{1-6}$ alkyl, $-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl, C_{1-6} alkanoyl, optionally substituted by C_{1-6} alkoxy, C_{1-6} haloalkanoyl, optionally substituted by C_{1-6} alkoxy, phenyl, het, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)-C(O)NR^aR^b$ or $-(C_{0-3}$alkylene$)-N(R^c)C(O)R^6$;

R^3 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl , $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$alkyl, $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)$-phenyl, $-(C_{0-3}$alkylene$)$-het, $-(C_{2-3}$alkenylene$)$-phenyl, $-(C_{2-3}$alkenylene$)$-het, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl or $-N(R^c)CO_2R^6$;

R^4 represents hydrogen, C_{1-6} alkyl, C_{1-6}haloalkyl, $-(C_{0-3}$alkylene$)-R^7$ or $-(C_{1-3}$alkylene$)-R^8$;

or R^3 and R^4 taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

R^5 represents hydrogen, hydroxy, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ or $-N(R^{12})R^{13}$;

R^6 represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R^7 represents C_{3-8}cycloalkyl, $-S(O)_nR^9$, phenyl, het, $-CO_2R^6$ or $C(O)N(R^a)R^b$;

R^8 represents hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, $-N(R^a)R^b$ or $-O-C(O)R^6$;

R^9 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8}cycloalkyl, $-N(R^a)R^b$, phenyl or het;

R^{10} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{11} represents hydrogen, hydroxy, C_{1-3}alkoxy, $-N(R^a)R^b$, phenyl, het or C_{3-8}cycloalkyl, with the proviso that $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ is not $-N=CH_2$;

R^{12} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl or C_{1-6} haloalkenyl;

R^{13} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl, C_{1-6} haloalkenyl C_{3-8}cycloalkyl, phenyl, het, $-(C_{1-6}alkylene)-R^{14}$, $-C(O)_pR^{15}$ or $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$;

R^{14} represents hydroxy, C_{1-3}alkoxy, C_{1-3}haloalkoxy, C_{3-8}cycloalkyl, phenyl, het or $-N(R^a)R^b$;

R^{15} represents C_{1-6} alkyl, C_{1-6} haloalkyl or $-(C_{1-6}alkylene)-C_{1-3}alkoxy$;

R^{16} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{17} represents hydrogen or $N(R^a)R^b$;

R^a and R^b independently represent hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl or C_{2-6} haloalkenyl, or R^a additionally represents $-(C_{0-3}alkylene)-C_{3-8}$ cycloalkyl, $-(C_{0-3}alkylene)-$phenyl or $-(C_{0-3}alkylene)-$het, or together R^a and R^b form a 4- to 7-

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkoxy and C_{1-6}haloalkoxy;

R^c represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, -(C_{0-3}alkylene)–C_{3-8} cycloalkyl, -(C_{0-3}alkylene)–phenyl or -(C_{0-3}alkylene)–het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, C_{3-8} cycloalkyl, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkoxycarbonyl and NR^aR^b;

where C_{3-6}cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, hydroxy, C_{1-6}alkoxy and C_{1-6}haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

2. A compound according to claim 1, wherein R^1 is a phenyl group which bears chloro substituents at the 2- and 6-positions, and a substitutent at the 4-position selected from trifluoromethyl, difluoromethoxy, trifluoromethoxy, trifluoromethylthio and pentafluorothio.

3. A compound according to claim 1 or 2, wherein R^2 is selected from ~~hydrogen~~, cyano, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, e.g. cyclopropyl, C_{1-6} alkanoyl and $-C(O)N(R^a)R^b$.

4. A compound according to claim 3, wherein R^2 is cyano.

5. A compound according to any one of claims 1-4, wherein R^3 is selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, $-(C_{1-3}alkylene)-S(O)_nC_{1-6}alkyl$, $-N(R^a)R^b$, C_{1-6} alkanoyl, $-N(R^a)CO_2R^6$, phenyl, optionally substituted by one or more halo, and benzyl.

6. A compound according to claim 5, wherein R^3 is methyl.

7. A compound according to any one of claims 1-6, wherein R^4 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{0-3}alkylene)-C_{3-8}$ cycloalkyl, cyanomethyl, 2-hydroxyethyl, $-(C_{1-2}alkylene)$-het, $-(C_{0-3}alkylene)$-phenyl, $-(C_{0-1}alkylene)-S(O)_nR^9$, $-(C_{1-3}alkylene)-O-C(O)R^6$, $-(C_{1-3}alkylene)-C(O)N(R^a)R^b$ and $-CO_2R^6$.

8. A compound according to claim 7, wherein R^4 is selected from hydrogen, methyl, ethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, methylsulfonyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, aminosulfonyl, N,N-dimethylaminosulfonyl, methylsulfonymethyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, 1-(trifluoromethyl)cyclopropylmethyl, cyanomethyl, methoxycarbonyl, triazolylethyl, pyrimidin-4-ylmethyl, 1,2,4-oxadiazol-3-ylmethyl, pyrazol-3-ylmethyl, 1-methyl-1H-imidazol-2-yl, 5-methyl-isoaxazol-3-ylmethyl, 2-pyridin-4-ylethyl, aminocarbonylmethyl, benzyl and 4-fluorobenzyl.

9. A compound according to any one of claims 1-8, wherein R^5 is selected from hydrogen, halo, C_{1-6} alkoxy, $-N=C(H)R^{11}$, where R^{11} is ethoxy, N,N-dimethyl or phenyl, and $-NR^{12}R^{13}$.

10. A compound according to claim 9, wherein R^5 is amino.

11. A compound of formula (I) selected from:

N-(5-amino-3-cyano-1-[2,6-dichloro-4pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2,2-difluoroethyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-1,1,1-trifluoro-*N*-methylmethanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-3,4-difluorobenzenesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(cyclopropylmethyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(cyanomethyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(pyridin-2-ylmethyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-benzylmethanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-[2-(dimethylamino)ethyl]methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-1-(methylsulfonyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl]-*N*-(2-hydroxyethyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-[(methylthio)methyl]methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)cyclopropanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-[(dimethylamino)sulfonyl]methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)methanesulfonamide;

N-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-1-phenylmethanesulfonamide;

(*E*)-*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-2-phenylethylenesulfonamide;

N-[5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxidoisothiazolidin-2-yl)-1*H*-pyrazole-3-carbonitrile;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1,1,1-trifluoro-*N*-methylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(cyclopropylmethyl)-1,1,1-trifluoromethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1,1,1-trifluoro-*N*-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-cyclobutyl-1,1,1-trifluoromethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1,1,1-trifluoro-*N*-methylmethanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[2-(1*H*-1,2,4-triazol-1-yl)ethyl]methanesulfonamide;

5-amino-4-[bis(methylsulfonyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazole-3-carboxamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-acetyl-5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[[1-(trifluoromethyl)cyclopropyl]methyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)ethanesulfonamide;

methyl 5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl(methylsulfonyl)carbamate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-methylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-fluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(1,2,4-oxadiazol-3-ylmethyl)methanesulfonamide;

N^2-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-N^2-(methylsulfonyl)glycinamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(1*H*-pyrazol-3-ylmethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,3,3,3-pentafluoropropyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-pyrrolidin-1-ylethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-morpholin-4-ylethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(1-methyl-1*H*-imidazol-2-yl)methyl]methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(5-methylisoxazol-3-yl)methyl]methanesulfonamide;

[{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}(methylsulfonyl)amino]methyl pivalate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-ethylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-benzylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(4-fluorobenzyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1-(methylsulfonyl)ethanesulfonamide;

N-{5-amino-1-[2-chloro-4-pentafluorothio-phenyl]-3-cyano-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(1,1-dioxido-1,2-thiazinan-2-yl)-1*H*-pyrazole-3-carbonitrile;

N-{5-(benzylamino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-{2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino}-1*H*-pyrazol-5-yl}-2-methoxyacetamide;

ethyl 4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-5-ylimidoformate;

N-{3-cyano-5-[(cyclopropylmethyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino}-1*H*-pyrazol-5-yl}acetamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-methoxy-1*H*-pyrazol-4-yl}methanesulfonamide;

N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(methylamino)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[(dimethylamino)methylene]amino}-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[2-(dimethylamino)ethyl]amino}-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-pyrrolidin-1-ylethyl)amino]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-morpholin-4-ylethyl)amino]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyclopropyl-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

~~*N*-{5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide~~

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(pyridin-4-ylmethyl)amino]-1*H*-pyrazol-4-yl}methanesulfonamide;

tert-butyl ({5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}amino)sulfonylcarbamate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-pyridin-4-ylethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(pyrazin-2-ylmethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(6-aminopyridin-3-yl)methyl]methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-2-oxo-*N*-(2,2,2-trifluoroethyl)propane-1-sulfonamide;

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[3-(dimethylamino)propyl]amino}-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}sulfamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-4-fluoro-*N*-(methylsulfonyl)benzenesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-2,4-difluoro-*N*-(methylsulfonyl)benzenesulfonamide;

methyl 3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-ylcarbamate;

N-{5-({[(2-aminoethyl)amino]carbonyl}amino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

trifluoroacetate salt of *N*-{5-[(2-azetidin-1-ylethyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;
N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[(2,4-dihydroxyphenyl)methylene]amino}-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;
N-{5-chloro-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide; or
N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-{[3-(dimethylamino)ethyl]amino}-1H-pyrazol-4-yl)-N-(methylsulfonyl)methanesulfonamide;
or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical or veterinary composition comprising a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, and a suitable excipient or carrier.

13. A compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, for use in medical therapy.

~~14. Use of a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, in the manufacture of a human or animal parasiticidal medicament.~~

~~15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically acceptable amount of compound according to any one claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof.~~

~~WO 2006/090313~~ 152 ~~142~~ ~~PCT/IB2005/000597~~

~~CLAIMS~~

14. Use of a compound of formula (I)

~~1. A compound of formula (I)~~ or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



(I)

wherein:

R^1 represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, $-S(O)_nC_{1-6}$alkyl, $-S(O)_nC_{1-6}$haloalkyl and pentafluorothio;

R^2 represents hydrogen, halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl, C_{2-6} haloalkynyl, $-S(O)_nC_{1-6}$ alkyl, $-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl, C_{1-6} alkanoyl, optionally substituted by C_{1-6} alkoxy, C_{1-6} haloalkanoyl, optionally substituted by C_{1-6} alkoxy, phenyl, het, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)-C(O)NR^aR^b$ or $-(C_{0-3}$alkylene$)-N(R^c)C(O)R^6$;

R^3 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl , $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$alkyl, $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)$-phenyl, $-(C_{0-3}$alkylene$)$-het, $-(C_{2-3}$alkenylene$)$-phenyl, $-(C_{2-3}$alkenylene$)$-het, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl or $-N(R^c)CO_2R^6$;

R^4 represents hydrogen, C_{1-6} alkyl, C_{1-6}haloalkyl, $-(C_{0-3}$alkylene$)-R^7$ or $-(C_{1-3}$alkylene$)-R^8$;

or R^3 and R^4 taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

R^5 represents hydrogen, hydroxy, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ or $-N(R^{12})R^{13}$;

R^6 represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R^7 represents C_{3-8}cycloalkyl, $-S(O)_nR^9$, phenyl, het, $-CO_2R^6$ or $C(O)N(R^a)R^b$;

R^8 represents hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, $-N(R^a)R^b$ or $-O-C(O)R^6$;

R^9 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8}cycloalkyl, $-N(R^a)R^b$, phenyl or het;

R^{10} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{11} represents hydrogen, hydroxy, C_{1-3}alkoxy, $-N(R^a)R^b$, phenyl, het or C_{3-6}cycloalkyl, with the proviso that $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ is not $-N=CH_2$;

R^{12} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl or C_{1-6} haloalkenyl;

R^{13} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl, C_{1-6} haloalkenyl C_{3-6}cycloalkyl, phenyl, het, $-(C_{1-6}alkylene)-R^{14}$, $-C(O)_pR^{15}$ or $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$;

R^{14} represents hydroxy, C_{1-3}alkoxy, C_{1-3}haloalkoxy, C_{3-6}cycloalkyl, phenyl, het or $-N(R^a)R^b$;

R^{15} represents C_{1-6} alkyl, C_{1-6} haloalkyl or $-(C_{1-6}alkylene)-C_{1-3}alkoxy$;

R^{16} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{17} represents hydrogen or $N(R^a)R^b$;

R^a and R^b independently represent hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl or C_{2-6} haloalkenyl, or R^a additionally represents $-(C_{0-3}alkylene)-C_{3-8}$ cycloalkyl, $-(C_{0-3}alkylene)$–phenyl or $-(C_{0-3}alkylene)$–het, or together R^a and R^b form a 4- to 7-

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkoxy and C_{1-6}haloalkoxy;

R^c represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, -(C_{0-3}alkylene)–C_{3-8} cycloalkyl, -(C_{0-3}alkylene)–phenyl or -(C_{0-3}alkylene)–het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, C_{3-8} cycloalkyl, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkoxycarbonyl and NR^aR^b;

where C_{3-8}cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, hydroxy, C_{1-6}alkoxy and C_{1-6}haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo/

in the manufacture of a human or animal parasiticidal medicament.

~~WO 2005/090312~~ 155 ~~142~~ ~~PCT/IB2005/000597~~

15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically acceptable amount of a ~~CLAIMS~~ ~~A~~ compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



(I)

wherein:

R^1 represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, $-S(O)_nC_{1-6}$alkyl, $-S(O)_nC_{1-6}$haloalkyl and pentafluorothio;

R^2 represents hydrogen, halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl, C_{2-6} haloalkynyl, $-S(O)_nC_{1-6}$ alkyl, $-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl, C_{1-6} alkanoyl, optionally substituted by C_{1-6} alkoxy, C_{1-6} haloalkanoyl, optionally substituted by C_{1-6} alkoxy, phenyl, het, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)-C(O)NR^aR^b$ or $-(C_{0-3}$alkylene$)-N(R^c)C(O)R^6$;

R^3 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, $-(C_{0-3}$alkylene$)-C_{3-8}$ cycloalkyl , $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$alkyl, $-(C_{1-3}$alkylene$)-S(O)_nC_{1-6}$haloalkyl, $-(C_{0-3}$alkylene$)-N(R^a)R^b$, $-(C_{0-3}$alkylene$)$-phenyl, $-(C_{0-3}$alkylene$)$-het, $-(C_{2-3}$alkenylene$)$-phenyl, $-(C_{2-3}$alkenylene$)$-het, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl or $-N(R^c)CO_2R^6$;

R^4 represents hydrogen, C_{1-6} alkyl, C_{1-6}haloalkyl, $-(C_{0-3}$alkylene$)-R^7$ or $-(C_{1-3}$alkylene$)-R^8$;

or R^3 and R^4 taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

R^5 represents hydrogen, hydroxy, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ or $-N(R^{12})R^{13}$;

R^6 represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R^7 represents C_{3-8}cycloalkyl, $-S(O)_nR^9$, phenyl, het, $-CO_2R^8$ or $C(O)N(R^a)R^b$;

R^8 represents hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, $-N(R^a)R^b$ or $-O-C(O)R^6$;

R^9 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8}cycloalkyl, $-N(R^a)R^b$, phenyl or het;

R^{10} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{11} represents hydrogen, hydroxy, C_{1-3}alkoxy, $-N(R^a)R^b$, phenyl, het or C_{3-8}cycloalkyl, with the proviso that $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ is not $-N=CH_2$;

R^{12} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl or C_{1-6} haloalkenyl;

R^{13} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl, C_{1-6} haloalkenyl C_{3-8}cycloalkyl, phenyl, het, $-(C_{1-6}alkylene)-R^{14}$, $-C(O)_pR^{15}$ or $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$;

R^{14} represents hydroxy, C_{1-3}alkoxy, C_{1-3}haloalkoxy, C_{3-8}cycloalkyl, phenyl, het or $-N(R^a)R^b$;

R^{15} represents C_{1-6} alkyl, C_{1-6} haloalkyl or $-(C_{1-6}alkylene)-C_{1-3}alkoxy$;

R^{16} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

R^{17} represents hydrogen or $N(R^a)R^b$;

R^a and R^b independently represent hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl or C_{2-6} haloalkenyl, or R^a additionally represents $-(C_{0-3}alkylene)-C_{3-8}$ cycloalkyl, $-(C_{0-3}alkylene)$–phenyl or $-(C_{0-3}alkylene)$–het, or together R^a and R^b form a 4- to 7-

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkoxy and C_{1-6}haloalkoxy;

R^c represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, -(C_{0-3}alkylene)–C_{3-8} cycloalkyl, -(C_{0-3}alkylene)–phenyl or -(C_{0-3}alkylene)–het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, C_{1-6}alkoxy, C_{1-6}haloalkoxy, C_{3-8} cycloalkyl, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkoxycarbonyl and NR^aR^b;

where C_{3-6}cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{1-6} alkenyl, C_{1-6}haloalkenyl, hydroxy, C_{1-6}alkoxy and C_{1-6}haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.